By accurately defining the drug exposure levels that affect QRS duration, researchers can establish safety margins, prioritise lower-risk compounds, and reduce the chance of late-stage failures due to cardiac toxicity
Early cardiac derisking: A clinically translatable hiPSC cardiomyocyte assayAchieve action potential recordings from intrinsically paced hiPSC-CMs with Metrion’s clinically predictive hiPSC cardiomyocyte assay.
Read more about our hiPSC cardiomyocyte assay.
By accurately defining the drug exposure levels that affect QRS duration, researchers can establish safety margins, prioritise lower-risk compounds, and reduce the chance of late-stage failures due to cardiac toxicity
We demonstrate the generation and validation of a stable CHO-hHCN2 cell line used as a cellular tool in the successful development of hHCN2 automated electrophysiology screening assays.